NYSE:TAK

Takeda Pharmaceutical (TAK) Stock Forecast, Price & News

$15.84

-0.09 (-0.56%)

(As of 05:25 PM ET)

Compare

Today's Range: $15.81
▼
$15.92
50-Day Range: $15.04
▼
$16.33
52-Week Range: $12.28
▼
$17.15

Volume: 1.33 million shs
Average Volume: 2.32 million shs
Market Capitalization: $50.13 billion

P/E Ratio: 22.00
Dividend Yield: 3.22%
Price Target: $21.33

Takeda Pharmaceutical MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 34.7% Upside
$21.33 Price Target
Short Interest: Healthy
0.21% of Float Sold Short
Dividend Strength: Weak
Based on Four Factors
Sustainability: N/A
News Sentiment: 0.28
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 28.57%
From $0.35 to $0.45 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.80 out of 5 stars

Medical Sector

72nd out of 968 stocks

Pharmaceutical Preparations Industry

17th out of 445 stocks

3.5

Analyst's Opinion

Consensus Rating
Takeda Pharmaceutical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $21.33, Takeda Pharmaceutical has a forecasted upside of 34.7% from its current price of $15.84.
Amount of Analyst Coverage
Takeda Pharmaceutical has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.21% of the float of Takeda Pharmaceutical has been sold short.
Short Interest Ratio / Days to Cover
Takeda Pharmaceutical has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Takeda Pharmaceutical has recently decreased by 5.96%, indicating that investor sentiment is improving significantly.

1.7

Dividend Strength

Dividend Yield
Takeda Pharmaceutical pays a meaningful dividend of 3.11%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Takeda Pharmaceutical does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of Takeda Pharmaceutical is 70.83%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on EPS estimates, Takeda Pharmaceutical will have a dividend payout ratio of 113.33% in the coming year. This indicates that Takeda Pharmaceutical may not be able to sustain their current dividend.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TAK.

1.8

News and Social Media Coverage

News Sentiment
Takeda Pharmaceutical has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Takeda Pharmaceutical this week, compared to 6 articles on an average week.
Search Interest
Only 7 people have searched for TAK on MarketBeat in the last 30 days. This is a decrease of -13% compared to the previous 30 days.
MarketBeat Follows
12 people have added Takeda Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Takeda Pharmaceutical insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.04% of the stock of Takeda Pharmaceutical is held by insiders.
Percentage Held by Institutions
Only 2.65% of the stock of Takeda Pharmaceutical is held by institutions.

3.1

Earnings and Valuation

Earnings Growth
Earnings for Takeda Pharmaceutical are expected to grow by 28.57% in the coming year, from $0.35 to $0.45 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Takeda Pharmaceutical is 22.00, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 122.65.
Price to Earnings Ratio vs. Sector
The P/E ratio of Takeda Pharmaceutical is 22.00, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 121.72.
Price to Earnings Growth Ratio
Takeda Pharmaceutical has a PEG Ratio of 7.33. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Takeda Pharmaceutical has a P/B Ratio of 1.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Takeda Pharmaceutical (NYSE:TAK) Stock

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, JCR Pharmaceuticals, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.

TAK Price History

30 days | 90 days | 365 days | Advanced Chart

TAK Stock News Headlines

September 22, 2023 | msn.com

FDA accepts Takeda’s NDA resubmission for eosinophilic esophagitis therapy

September 20, 2023 | fool.com

Takeda Pharmaceutical (OTC: TKPHF)

September 22, 2023 | Chaikin Analytics (Ad)

This Stock Could Go Up 66% or More.

Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.

September 20, 2023 | finance.yahoo.com

Takeda Announces FDA Acceptance of NDA Resubmission of TAK-721 (budesonide oral suspension) for the Short-Term Treatment of Eosinophilic Esophagitis (EoE)

September 15, 2023 | benzinga.com

Contract Research Organisations (CROs) market is projected to grow at a CAGR of 10.6% by 2033: Visiongain

September 15, 2023 | americanbankingnews.com

Contrasting Takeda Pharmaceutical (NYSE:TAK) & Bolt Biotherapeutics (NASDAQ:BOLT)

September 12, 2023 | finance.yahoo.com

IntegriChain Expert to Speak on the Inflation Reduction Act at MDRP Summit

September 12, 2023 | finance.yahoo.com

Patient-led Innovations in Inflammatory Bowel Disease Take the Prize in Takeda Canada's Digital Health Challenge

September 22, 2023 | Chaikin Analytics (Ad)

This Stock Could Go Up 66% or More.

Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.

September 11, 2023 | benzinga.com

DelveInsight Evaluates a Robust Encephalopathy Clinical Trial as 70+ Influential Pharma Companies to Set Foot in the 7MM

September 11, 2023 | markets.businessinsider.com

Takeda Reports Positive Topline Results Of Phase 2b Study Of TAK-279 For Active Psoriatic Arthritis

September 11, 2023 | finance.yahoo.com

Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a Highly Selective Oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis

September 10, 2023 | msn.com

DCGI to keep vigil on sale of 2 drugs

September 6, 2023 | finance.yahoo.com

Google's investment arm leads $210M raise for biotech partnered with Takeda, Lilly

September 5, 2023 | benzinga.com

Dengue Clinical Trial Pipeline Insights | 20+ Key Companies Investigating Their Lead Candidates to Improve the Treatment Space by DelveInsight

September 5, 2023 | benzinga.com

Gastric Cancer Drugs Market to grow by USD 12.764 billion from 2022 to 2027; The increasing prevalence of gastric cancer drives the market - Technavio

August 31, 2023 | msn.com

Takeda: Innovative But Volatile, Fairly Priced For The Risk (Downgrade)

August 31, 2023 | finance.yahoo.com

Generic drugmakers start shipping copies of Takeda's ADHD drug Vyvanse

August 29, 2023 | msn.com

Takeda collaborates with ImmunoGen for ELAHERE

August 27, 2023 | finance.yahoo.com

Ireland seeks to lure life science investment despite corporate tax rise

August 24, 2023 | uk.finance.yahoo.com

Hereditary Angioedema Therapeutics Global Market Report 2023

August 24, 2023 | finance.yahoo.com

Hepatocellular Carcinoma Drugs Global Market Report 2023

August 24, 2023 | finance.yahoo.com

Non Hodgkin Lymphoma (NHL) Global Market Report 2023

August 24, 2023 | msn.com

Takeda, Cancer Warriors unite for better cancer care access

August 23, 2023 | finance.yahoo.com

2 Ultra-Cheap High-Yield Dividend Stocks to Buy Now

August 15, 2023 | nytimes.com

As the School Year Begins, Families Struggle to Find A.D.H.D. Medication

August 14, 2023 | finance.yahoo.com

Multiple Myeloma Market to Observe Impressive Growth at a CAGR of ~5% During the Study Period (2019-2032), Assesses DelveInsight

See More Headlines

Receive TAK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Takeda Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

TAK Company Calendar

Last Earnings: 7/27/2023
Today: 9/22/2023
Next Earnings (Estimated): 10/26/2023
Fiscal Year End: 3/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:TAK
CUSIP: N/A
CIK: 1395064
Web: www.takeda.com
Phone: (166) 204-2111
Fax: 813-3278-2268
Employees: 49,095
Year Founded: 1781

Price Target and Rating

Average Stock Price Forecast: $21.33
High Stock Price Forecast: $30.00
Low Stock Price Forecast: $14.00
Forecasted Upside/Downside: +34.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.72
Trailing P/E Ratio: 22.01
Forward P/E Ratio: 45.29
P/E Growth: 7.33
Net Income: $2.35 billion
Net Margins: 7.34%
Pretax Margin: 8.38%
Return on Equity: 12.54%
Return on Assets: 5.77%

Debt

Debt-to-Equity Ratio: 0.63
Current Ratio: 0.99
Quick Ratio: 0.56

Sales & Book Value

Annual Sales: $29.81 billion
Price / Sales: 1.68
Cash Flow: $3.49 per share
Price / Cash Flow: 4.54
Book Value: $14.86 per share
Price / Book: 1.07

Miscellaneous

Outstanding Shares: 3,164,690,000
Free Float: 3,163,426,000
Market Cap: $50.16 billion
Optionable: Optionable
Beta: 0.62

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Mr. Christophe Weber (Age 57)
Pres, CEO & Representative Director
Comp: $3.93M

Mr. Constantine Saroukos (Age 52)
CFO & Representative Director
Comp: $2.45M

Dr. Andrew S. Plump (Age 58)
Pres of R&D and Representative Director
Comp: $2.8M

Dr. Seigo Izumo
Chair of Management Board

Mr. Haruhiko Hirate (Age 66)
Member of Management Board

Salvatore Alesci
Member of Management Board and Head of R&D Global Science & Biomedical Policy

Norimasa Takeda
Chief Accounting Officer & Corp. Controller

Mr. Iwaaki Taniguchi
Sr. VP of Corp. Fin. & Controlling Department

Mr. Gabriele Ricci (Age 45)
Chief Data & Technology Officer

Mr. Christopher David O'Reilly
Global Head of Investor Relations & Global Fin.

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

TAK Stock - Frequently Asked Questions

Should I buy or sell Takeda Pharmaceutical stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Takeda Pharmaceutical in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TAK shares.
View TAK analyst ratings or view top-rated stocks.
What is Takeda Pharmaceutical's stock price forecast for 2023?: 2 brokers have issued 12-month price targets for Takeda Pharmaceutical's stock. Their TAK share price forecasts range from $14.00 to $30.00. On average, they anticipate the company's stock price to reach $21.33 in the next twelve months. This suggests a possible upside of 34.6% from the stock's current price.
View analysts price targets for TAK or view top-rated stocks among Wall Street analysts.
How have TAK shares performed in 2023?: Takeda Pharmaceutical's stock was trading at $15.60 at the beginning of 2023. Since then, TAK stock has increased by 1.6% and is now trading at $15.85.
View the best growth stocks for 2023 here.
When is Takeda Pharmaceutical's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023.
View our TAK earnings forecast.
How were Takeda Pharmaceutical's earnings last quarter?: Takeda Pharmaceutical Company Limited (NYSE:TAK) announced its quarterly earnings data on Thursday, July, 27th. The company reported $0.55 earnings per share (EPS) for the quarter. The business had revenue of $7.71 billion for the quarter. Takeda Pharmaceutical had a net margin of 7.34% and a trailing twelve-month return on equity of 12.54%.
What ETFs hold Takeda Pharmaceutical's stock?: ETFs with the largest weight of Takeda Pharmaceutical (NYSE:TAK) stock in their portfolio include VanEck Pharmaceutical ETF (PPH), ActivePassive International Equity ETF (APIE), B.A.D. Etf (BAD) and First Trust International IPO ETF (FPXI).ETFMG Treatments Testing and Advancements ETF (GERM).
Is Takeda Pharmaceutical a good dividend stock?: Takeda Pharmaceutical (NYSE:TAK) pays an annual dividend of $0.51 per share and currently has a dividend yield of 3.11%. The dividend payout ratio is 70.83%. This payout ratio is at a healthy, sustainable level, below 75%. Based on EPS estimates, TAK will have a dividend payout ratio of 113.33% in the coming year. This indicates that the company may not be able to sustain their current dividend.
What guidance has Takeda Pharmaceutical issued on next quarter's earnings?: Takeda Pharmaceutical issued an update on its FY 2023 earnings guidance on Thursday, July, 27th. The company provided earnings per share guidance of $3.16-$3.16 for the period. The company issued revenue guidance of $27.99 billion-$27.99 billion.

What other stocks do shareholders of Takeda Pharmaceutical own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Takeda Pharmaceutical investors own include Cisco Systems (CSCO), Johnson & Johnson (JNJ), Alibaba Group (BABA), Pfizer (PFE), Verizon Communications (VZ), AbbVie (ABBV), CVS Health (CVS), Gilead Sciences (GILD), AT&T (T) and Abbott Laboratories (ABT).
What is Takeda Pharmaceutical's stock symbol?: Takeda Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "TAK."
Who are Takeda Pharmaceutical's major shareholders?: Takeda Pharmaceutical's stock is owned by many different institutional and retail investors. Top institutional shareholders include Capital Research Global Investors (0.44%), Goldman Sachs Group Inc. (0.15%), Renaissance Technologies LLC (0.12%), Clal Insurance Enterprises Holdings Ltd (0.09%), BlackRock Inc. (0.08%) and Point72 Asset Management L.P. (0.07%).
How do I buy shares of Takeda Pharmaceutical?: Shares of TAK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Takeda Pharmaceutical's stock price today?: One share of TAK stock can currently be purchased for approximately $15.85.
How much money does Takeda Pharmaceutical make?: Takeda Pharmaceutical (NYSE:TAK) has a market capitalization of $50.16 billion and generates $29.81 billion in revenue each year. The company earns $2.35 billion in net income (profit) each year or $0.72 on an earnings per share basis.
How many employees does Takeda Pharmaceutical have?: The company employs 49,095 workers across the globe.
Does Takeda Pharmaceutical have any subsidiaries?: The following companies are subsidiares of Takeda Pharmaceutical: ARIAD Pharmaceuticals, Baxalta Manufacturing S.à r.l., IDM Pharma Inc., Intellikine, Inviragen, LigoCyte Pharmaceuticals, Meritage Pharma Inc., Millennium Pharmaceuticals, Millennium Pharmaceuticals Inc., Nihon Pharmaceutical Co. Ltd., Nycomed Pharma, PvP Biologics, Shire, Shire ViroPharma LLC, Takeda (China) Holdings Co. Ltd., Takeda AS, Takeda Austria GmbH, Takeda Bio Development Center, Takeda California Inc., Takeda Consumer Healthcare Company Limited, Takeda Development Center Americas Inc., Takeda Development Center Asia Pte. Ltd., Takeda Development Centre Europe Ltd., Takeda Distribuidora Ltda., Takeda France S.A.S., Takeda GmbH, Takeda Ireland Limited, Takeda Italia S.p.A., Takeda Pharma A/S, Takeda Pharmaceutical (China) Company Limited, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals Korea Co. Ltd., Takeda Pharmaceuticals Limited Liability Company, Takeda Pharmaceuticals U.S.A. Inc., Takeda UK Limited, Takeda Vaccines Inc., Takeda Vaccines Pte. Ltd., and TiGenix.
Read More
How can I contact Takeda Pharmaceutical?: Takeda Pharmaceutical's mailing address is 1-1 NIHONBASHI-HONCHO 2-CHOME CHUO-KU, TOKYO M0, 103-8668. The official website for the company is www.takeda.com. The company can be reached via phone at (166) 204-2111, via email at takeda.ir.contact@takeda.com, or via fax at 813-3278-2268.

This page (NYSE:TAK) was last updated on 9/22/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial